- Location
commercialization rights
"-
Nomad Foods Completes Acquisition of Findus Sverige for £500m
Nov 4, 2015British Virgin Islands-based packaged food company Nomad Foods has completed the acquisition of frozen food brand Findus Sverige AB for £500m from LionGem Sweden 1 AB. The acquisition includes Findus' European businesses in ...
Tags: Nomad Foods, frozen food, Findus
-
Zymeworks Has Entered Into a Licensing and Collaboration Agreement with ImClone Systems
Jan 9, 2014Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody ...
-
Agios Pharmaceuticals Has Announced an Extension of One Additional Year
Dec 13, 2013US-based Agios Pharmaceuticals has announced an extension of one additional year to the period of exclusivity for their strategic cancer metabolism collaboration with Celgene. Celgene research president Dr Thomas Daniel noted the quality ...
-
Proteostasis Therapeutics, Biogen Idec Collaborated to Research and Develop New Therapies
Dec 11, 2013Proteostasis Therapeutics and Biogen Idec have collaborated to research and develop new therapies based on the inhibition of Usp14, a deubiquitinating enzyme, for the treatment of certain neurodegenerative disorders. Under the deal, ...
-
Teva Pharmaceutical Has Licensed Rights to Commercialize Glatiramer Acetate
Dec 9, 2013Teva Pharmaceutical has licensed rights to commercialize glatiramer acetate to Takeda Pharmaceutical in Japan as part of their agreement signed earlier in 2013. Currently both the firms are working on additional agreements for ...
Tags: Teva Licenses, Medicine
-
The US Food and Drug Administration Has Granted Orphan Drug Status
Dec 6, 2013OncoMed Pharmaceuticals and Celgene have entered into an agreement to jointly develop and commercialize about six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4). ...
Tags: clinical studies, Medicine, OncoMed
-
Helsinn Gives Rights to Their Ghrelin Receptor Agonist to Chugai Pharma Marketing
Nov 14, 2013Switzerland-based Helsinn group has granted Chugai Pharma Marketing, a wholly-owned subsidiary of Chugai Pharmaceutical, exclusive commercialization rights to their ghrelin receptor agonist, anamorelin, for the three major European pharma ...
Tags: Helsinn group, Pharma Marketing
-
Stallergenes, DBV Entered Into an Agreement for Treatment of Birch Allergy
Oct 22, 2013France-based biopharmaceutical firms Stallergenes and DBV Technologies have entered into a research and development agreement for the treatment of birch allergy. Stallergenes is specialized in the manufacturing of immunotherapy medicines ...
-
ThromboGenics Has Obtained Approval for Jetrea for The Treatment of Symptomatic VMA
Aug 20, 2013Integrated biopharmaceutical company ThromboGenics has obtained Health Canada approval for Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). Launch of the drug in Canada will be conducted by Alcon, ...
-
FDA Has Accepted The New Drug Application (NDA)From DURECT
Jun 24, 2013The US Food and Drug Administration (FDA) has accepted the new drug application (NDA)from DURECT, a specialty pharmaceutical company, for its Posidur (Saber-Bupivacaine) investigational candidate. Designed to offer up to three days of ...
-
DBV Technologies and Stallergenes Partner to Treat Respiratory Allergies
May 21, 2013DBV Technologies and Stallergenes have entered into a strategic research partnership to develop immunotherapy treatments for respiratory allergies using DBV's skin patch, Viaskin. The collaboration combines Stallergenes' know-how in ...
-
Abide, Merck Have Collaborated to Develop New Therapies for Type 2 Diabetes
May 6, 2013Abide Therapeutics and Merck, referred to as MSD outside the US and Canada, have collaborated to develop new therapies for type 2 diabetes and metabolic diseases. The collaboration will focus on the discovery, development and ...
Tags: Abide Therapeutics, Medicine
-
Paladin Labs Has Launched Silenor (Doxepin Hydrochloride) in Canada
May 3, 2013Paladin Labs has launched Silenor (doxepin hydrochloride), specified for the treatment and symptomatic relief of insomnia with characteristics of frequent nocturnal awakening and/or early morning awakenings, in Canada. Silenor, which is ...
-
Pfizer and Protalix BioTherapeutics Have Obtained Approval for Uplyso
Mar 20, 2013Pfizer and Protalix BioTherapeutics have obtained approval from the Brazilian National Health Surveillance Agency for Uplyso (alfataliglicerase) as type I Gaucher disease therapy. Uplyso, referred to as Elelyso (taliglucerase alfa) ...
Tags: Pfizer, Protalix, Protalix BioTherapeutics
-
Sanofi Has Launched Epinephrine Auto-Injector
Feb 1, 2013Sanofi has launched epinephrine auto-injector, designed for use in patients with extreme allergic reactions, in the US. Auvi-Q (epinephrine injection), which the company claims is the first-and-only epinephrine auto-injector with audio ...
Tags: Sanofi, epinephrine auto-injector, patients